LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT
REAL TIME PRESS COVERAGE & Reporter: Aviva Lev-Ari, PhD, RN
Summer Symposium 2017
https://ki.mit.edu/news/symposium/2017

@kochinstitute #KIsymposium @Pharma_BI @AVIVA1950
A leader in Convergence, MIT’s Koch Institute for Integrative Cancer Research will, on June 16, present its 16th annual Summer Symposium: the Convergence of Science and Engineering in Cancer Research. Convergence—the merging of historically distinct disciplines such as engineering, physics, computer science, chemistry, mathematics, and the life sciences—has created extraordinary opportunities in cancer research and care. Leaders in this emerging field will discuss innovative new approaches and technologies to better detect, monitor, treat, and prevent cancer. The symposium will also feature a panel of experts to discuss the impact of Convergence on the future of medical care.
INTRODUCTORY REMARKS
![]() |
Tyler Jacks, PhD Director, Koch Institute, MIT David H. Koch Professor of Biology, MITLIVE – new Solutions for Cancer the mission og KI. Sponsors: Affiliates, Collaborators, Patrons, Friends, Vendors. Introduction to Prof. Sharp. 40th Anniversary of RNA related discovery leading to Nobel Prize of Prof. Sharp. Concluding the Symposium
|
![]() |
Phillip A. Sharp, PhD LIVE – Convergence of Science and Engineering. Key note by a convergent personality – Eric Lander. Convergence is a blueprint for innovation – NOW transformation of Life Science that follows the transformation of Physical sccience. Molecular biology – Delbruck, transmission of genetic phenotypes. Revolution of Biological Sciences in 20th Century 1st Revolution – DNA Structure, 1953 2nd Revolution – genomics Human Genome 2003 3rd Revolution – Integration of Science and the Environment in 21st Century Such Small investment, 3.4% of NI Funding went to PI in BioEngineering 2000-2016 Introduction to Eric Lander – 1986 – to Whitehead Institute and MIT, now at Broad |
KEYNOTE SPEAKER
![]() |
30 Years of ConvergenceEric Lander, PhD LIVE – Personal Reflection on Convergence in BioMedicine Process is important inconvergence — WHAT ARE WE CONVERGING TOWARD? 1985 — today — 2045 BioMedicine – born from 4 Intellectual Revolutions:
GENOMICS comes along: a View of
Comprehensive viewsDiscovering Disease Genes – 1980s: Mendelian rare inherited, Common variation, Somatic
Human Genome Variations Discovering Disease Genes – 2000s: 2017: 100 diseases are derived from Genome variation
Programmable Genome Targeting –
Human cells – unified coordinated to classify Cells and Tissues
Comprehensive Tools
|
SPEAKERS
![]() |
Synthetic biology and next-generation diagnosticsJames Collins, PhD LIVE Synthetic Biology – Reprogramming life
Potential for Synthetic Gene Biology
|
![]() |
Cancer Genome and the CloudGad A. Getz, PhD LIVE – Cancer is a disease of the Genome and epigenome – Life history of a Tumor
Mutational Signatures
BRCA1/2: Signature analyzer: Breast Cancer mutation signatures
Mono-alleleic inactivation of BRCA Germline mutation PALB2 PAthogenic mutations in genes RAD51C – the third BRCA Signature 3 is associated with BRCA
|
![]() |
Targeting Aggressive Cancers Nanolayers at a Time: A Platform Approach to Engineered NanomedicinePaula T. Hammond, PhD LIVE
|
![]() |
New chemical engieering approaches to convergenceRobert S. Langer, ScD LIVE
Combinatorial lipid synthesis Next generation LNPs: with novel lipids – potency improvement Nano formulations for Entdothelium – combinatorial generation Nano particle library Current techniques:Electroporation
Conversion : Clinicians and Engineers |
![]() |
Understanding transcription and splicing heterogeneity in cancer progressionDaniel Larson, PhD Daniel Larson, NCI – Transcription and Splicing in Heterogeneity in Cancer ProgressionLIVE
|
![]() |
Computational Models of CancerFranziska Michor, PhD LIVE
|
![]() |
Spherical Nucleic Acids as a Powerful New Platform for Cancer TherapyChad A. Mirkin, PhD LIVE Next wave of Pharmaceuticals
SNA Competitive advantage |
Dissecting the tumor ecosystem with single cell genomics
Aviv Regev, PhD Director, Klarman Cell Observatory and Cell Circuits Program, Broad Institute of Harvard and MIT LIVE – Tumors: A complex cellular Ecosystem
Cell-types and states in the melanoma ecosystem:
Treatment naive vs Immunotherapy resistant (ITR) – CD8 cells from ITR sample – intratumor variation How malignant melanocyte affect T-cells?
|
|
![]() |
Illuminating biology at the nanoscale and systems scale using single-molecule and super-resolution imagingXiaowei Zhuang, PhD Session I: NEW VIEWXiaowei Zhuang, Harvard University — Single-Cell Transcriptome and Genome Imaging,
LIVE
Modified Hamming distance 4 – multiplexed, hydridization Applications:
|
EXPERT PANEL: CONVERGENCE IN HEALTH
![]() |
LIVE
Cori Bargmann, PhD LIVE – translation of the needs in computational, biology, IT, mathematician, medicine, physics and engineering. BRAIN Initiative at NIH. How to motivate? by a Problem in need for solution
|
![]() |
Marc N. Casper, MBA LIVE – convergence from a tool perspectiveLast 20 years – integration of Biology into the physical sciences, SCREENING AND DIAGNOSTICS |
![]() |
Victor Dzau, MD LIVE As cardiologist: Pace maker Convergence in Research. Funding research does not encourage convergence innovation is killing disease, need to introduce cost effectiveness – economics into the play. Recognition of cost in Precision Medicine: economic model as a tool to consider cost effectiveness, Convergence to include SOcial Sciences and Economics Diagnostics; |
![]() |
Tyler Jacks, PhD LIVE – Convergence at Koch NIH created few CENTERS for research in Cancer, Brain, Nanotech, focus on Cancer did help the convergence Next step of Convergence: common language, Learning by doing, mechanisms to encourage and continue the convergence Better efficiency:
|
![]() |
Nancy Simonian, MD LIVE – convergence is required to understand the biology of a disease, genomics, computational biology and chemistry is a new approach Cost of Medicines: reibbursement per value vs no concern to value. Innovation t carry premium allowing cost reduction while effciency is been exploled. |
![]() |
Elias Zerhouni, MD LIVE Convergence of multidisciplines is a must for scientific solutions to emerge, horizontal integration Patient Bill of Right Defficiet every year in the US, |
![]() |
Moderated by:Susan Hockfield, PhD
|
Leave a Reply